

Hua Medicine

华领医药

China Healthcare Summit

November 14, 2018

Glucokinase GK is a Glucose Sensor in Glucose Homeostasis

Hua Medicine

Source: Franz Matschinsky, Mol. and Cell Biology of Type 2 Diabetes and Its Complications, 1998, vol 4, pp 14-29

[1] A common measure of blood glucose levels is hemoglobin A1c, or HbA1c, which measures average glycated blood glucose levels for the 3 months prior to testing. HbA1c levels for people without diabetes is between 4% and 5.6% (equivalent to 4-5.6 mmol/liter), for people with impaired glucose tolerance (IGT), or pre-diabetics, is between 5.74% and 6.4% (equivalent to 5.74 -6.4 mmol/liter) and for people with diabetes is 6.5% or higher (equivalent to 6.5 mmol/liter or higher).

[2] In addition to GK (also referred to as hexokinase type 4), Hexokinase types 1-3 play a role in the glucose homeostasis process. Unlike a properly functioning GK, which is only active at blood glucose levels over 5.5 mmol/liter, hexokinase types 1-3 are active in the presence of even small amounts of glucose in the bloodstream – providing a basal

Sustained Efficacy in HbA1c Reduction

Proof of Concept in Phase II Study


Hua Medicine

Dorzagliatin: Proof-of-Concept (POC) Achieved with Sustained Efficacy

Double blinded, placebo controlled and randomized Phase II trial with 258 patients in China over 22 clinical centers

Published in Lancet in May 2018


Dorzagliatin reduced HbA1c levels dose dependently...



The chart above showcases HbA1c change from baseline after the 12-week treatment period (PPS, LOCF[4])[5], with the results showing that Dorzagliatin reduced HbA1c levels dose dependently with 75 mg QD, 100 mg QD, 50 mg BID and 75 mg BID, after the treatment period

In the 75mg BID group, both fasting plasma glucose level (FPG) and post-prandial glucose level (PPG) were well controlled without increasing hypoglycemia or dyslipidemia risk

...with the 75 mg BID group showing HbA1c reduction effect starting from week four



The chart above showcases HbA1c change from baseline over time (PPS)[6]

[1] P<0.05 compared to placebo group. [2] P<0.01 compared to placebo group. [3] P<0.001 compared to placebo group. [4] LOCF represents for "last observation carried forward".
[5] The averages calculated applied least-square mean averages. [6] The averages calculated applied mean square averages.


Dorzagliatin Improved β-cell Function and Decreased Insulin Resistance

Hua Medicine

Phase III Trial Designed and Powered for Success


Hua Medicine

Study Design for:
Phase III GKA Mono-therapy Trial for Drug Naive T2D Patients (~450 Patients)
Phase III GKA Metformin Add-on Therapy Trial for Metformin Users (~750 Patients)



The best marketing is our clinical trials

Hua Medicine




World-renowned Senior Advisor, Portfolio Advisory Board and Influential Key Opinion Leaders

Chinese KOLs

Hua Medicine

Support from Renowned Shareholders

Hua Medicine


Hua Medicine